Parallax Volatility Advisers, L.P. Global Blood Therapeutics, Inc. Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $169,160 - $355,967	5,221 New	5,221 $356,000
Q3 2021 Nov 15, 2021	SELL	$25.48 - $37.34 $514,874 - $754,529	-20,207 Reduced 70.16%	8,593 $219,000
Q2 2021 Aug 16, 2021	BUY	$32.46 - $43.42 $934,848 - $1.25 Million	28,800 New	28,800 $1.01 Million
Q4 2019 Feb 14, 2020	SELL	$45.7 - $81.86 $776 - $1,391	-17 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$45.35 - $57.91 $90,246 - $115,240	-1,990 Reduced 99.15%	17 $0
Q1 2019 May 15, 2019	SELL	$39.99 - $53.48 $304,523 - $407,250	-7,615 Reduced 79.14%	2,007 $106,000
Q4 2018 Feb 14, 2019	SELL	$31.54 - $46.67 $1.57 Million - $2.32 Million	-49,738 Reduced 83.79%	9,622 $395,000
Q3 2018 Nov 14, 2018	SELL	$38.0 - $51.1 $777,784 - $1.05 Million	-20,468 Reduced 25.64%	59,360 $2.26 Million
Q2 2018 Aug 14, 2018	BUY	$38.7 - $50.15 $3.09 Million - $4 Million	79,828 New	79,828 $3.61 Million
Q1 2018 May 15, 2018	SELL	$39.6 - $65.9 $923,868 - $1.54 Million	-23,330 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$29.7 - $45.7 $692,901 - $1.07 Million	23,330	23,330 $918,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.